Trial Condition(s):

Bioequivalence

To establish the bioequivalence between riociguat tablet 1.0 mg intended to be marketed (# 502) and riociguat tablet 1.0 mg used for clinical samples (#512) in Japanese healthy adult male subjects

Bayer Identifier:

14845

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available

Study Completed

Trial Purpose

Please see attached Study Results Summary below.

Inclusion Criteria

No Inclusion Criteria Available

Exclusion Criteria

No Exclusion Criteria Available

Trial Summary

Enrollment Goal

Trial Dates

September2010

November2010

Phase

Could I receive a placebo?

Products

Adempas (Riociguat, BAY63-2521)

Accepts Healthy Volunteers

N/A

Where to Participate

Locations

Locations
Locations Osaka Pharmacology Clinical Research Hospital Osaka, Japan, 532-0003	Contact Us: E-mail: [email protected] Phone: Not Available

Osaka Pharmacology Clinical Research Hospital

Osaka, Japan, 532-0003

Contact Us:

E-mail: [email protected]

Phone: Not Available

Bioequivalence

Bayer Identifier:

ClinicalTrials.gov Identifier:

EudraCT Number:

EU CT Number:

Trial Purpose

Key Participation Requirements

sex

age

No Limit

Inclusion Criteria

Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Trial Summary

Enrollment Goal

Trial Dates

Phase

Could I receive a placebo?

Products

Accepts Healthy Volunteers

Where to Participate

For details, please refer to trial results

Additional Information